Compare Eli Lilly And Co (LLY) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs iShares Silver Trust — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while iShares Silver Trust trades at $54.78 (market cap $29.02B). The key difference: Eli Lilly And Co is far larger — about 35.8× iShares Silver Trust's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and iShares Silver Trust for 89 Days on average.
| LLY | SLV | |
|---|---|---|
Market Cap | $1.04T | $29.02B |
Volume | 3,064,878 | 16,510,334 |
Sector | Health | — |
52-Week High | $1.28K | $105.57 |
52-Week Low | $799.57 | $42.40 |
Typical Hold Time | 93 Days | 89 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
SLV (iShares Silver Trust) trades at $53.45, down 0.69% with a bearish technical signal. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Assets surged to $13.41B while liabilities remain negligible at $5.98K. Technical indicators show oversold conditions with RSI at 26.02, though moving averages signal continued bearish pressure.
The outlook remains challenged by Federal Reserve policy uncertainty and rising Treasury yields pressuring precious metals. While oversold conditions may provide short-term bounce potential, the fundamental case lacks revenue generation. Investors face headwinds from dollar strength and hawkish Fed expectations, requiring careful risk management in this volatile sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
